Benzinga's Microcap Movers for Monday August 27, 2012

Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves: DayStar Technologies Shares of DayStar Technologies DSTI, the Milpitas, CA manufacturer of low-cost, high performance, CIGS thin film photovoltaic products, rose 25.46% Monday on 21 tiems average volume. On August 21, 2012, DayStar Technologies, Inc. (the "Company") and each of Robert Weiss and Christopher T. Lail, former officers of the Company, entered into a separation agreement and settling all outstanding claims against the Company. Each of Mr. Weiss and Mr. Lail executed a Settlement Agreement and Release (the "Release"), whereby such person and the Company have agreed to provide full settlement and discharge of all claims which are or might be asserted in any forum related to their employment with the Company through June 30, 2012. In exchange for the Release, the Company was not required to make any cash payments but instead agreed to issue a convertible note with an initial principal amount of $700,000 to Mr. Weiss, and a convertible note with an initial principal amount of $300,000 to Mr. Lail. Each of these convertible notes is convertible into shares of common stock of the Company at a conversion price equal to the last closing consolidated bid price of the common stock on the Nasdaq at the time of the execution of the settlement agreement. In conjunction with the above mentioned Release, Robert Weiss effectually resigned as an officer of the Company retroactively effective as of March 31, 2012. DayStar Technologies closed at $0.98 on Monday. JinkoSolar Holding Shares of JinkoSolar Holding JKS, the China-based PV manufacturer, rose 16.49% Monday on twice the average volume. JinkoSolar announced Monday that it has won a bid from China Guangdong Nuclear Solar Energy Development to supply 30 MW of photovoltaic modules for a PV power plant project planned in Hami city, Xinjiang Province, China. "We are pleased that China Guangdong Nuclear has decided to extend its relationship with us by cooperating on this project in Xinjiang." said Mr. Xiande Li, Chairman of the board of Directors of JinkoSolar. "We believe that this validates our efforts to grow long-term relationship with major players in China's solar power plant industry and that this repeat order is a testament to the quality of our products and services. Our reputation as one of the industry-leading solar module producers with high quality products and services in the market continues to provide us with opportunities not only in China, but across the globe as we expand our geographic footprint worldwide." JinkoSolar Holding closed at $3.32 on Monday. Pristine Solutions Shares of Pristine Solutions (PRTN), the Beverly Hills, CA marketer of Tropine 3, rose 62.67% Monday on 110 million shares. Pristine Solutions announced Monday that the Company has completed the acquisition of Eaton Scientific Systems, a biomedical product development company focused on women's health solutions. Eaton Scientific has identified, developed, and filed a patent for a novel indication of an existing FDA approved drug, homatropine, for the non-hormonal treatment of hot flashes in pre-menopausal, pari-menopausal, and post-menopausal women. The drug indication, that Eaton Scientific named Tropine 3, is currently being prescribed and compounded by doctors in the Los Angeles, California specifically for their patients who have hot flash symptoms and do not want to take hormonal treatment. The drug, homatropine, is an anticholinergic medication that is an antagonist at muscarinic acetylcholine receptors and thus the parasympathetic nervous system. It is used in eye drops as a cycloplegic, and as a mydriatic in order to dilate the pupil. Homatropine is also given as an atropine substitute given to reverse the muscarinic and CNS effects associated with indirect cholinomimetic administration. Homatropine has been prescribed continuously and safely in the United States for over 40 years. Pristine Solutions closed at $0.37 on Monday. The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.